DSGN

+ Watchlist + Portfolio

Design Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $15.56
52-Week Range: $4.92 – $17.25
Market Cap: $938.10M
P/E (TTM): —
EPS (TTM): -1.18
Dividend Yield: —

Advanced Metrics

Price/Book: 4.65
PEG Ratio: —
Return on Equity: -34.13%
Return on Assets: -22.53%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 18.86
Debt/Equity: 0.01
Total Debt: $2.66M
Free Cash Flow: $-32.36M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $733.36M

DSGN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$48.61M	$57.06M	$44.35M	$59.13M
Selling, General & Admin	$18.98M	$21.13M	$18.03M	$20.34M
Operating Expenses	$67.59M	$78.19M	$62.38M	$79.47M
Operating Income	-$67.59M	-$78.19M	-$62.38M	-$79.47M
EBITDA	-$67.19M	-$77.65M	-$61.79M	-$78.84M
Pretax Income	-$63.31M	-$66.86M	-$49.59M	-$69.79M
Net Income	-$63.31M	-$66.86M	-$49.59M	-$69.79M
Diluted EPS	-1.14	-1.19	-0.88	-1.22
Diluted Shares	55.71M	55.98M	56.59M	57.33M

DSGN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$26.50M	$21.20M	$22.56M	$16.86M
Receivables	$1.11M	$1.43M	$1.26M	$1.68M
Current Assets	$335.12M	$284.58M	$248.04M	$223.78M
Total Assets	$341.14M	$289.64M	$252.09M	$226.20M
Current Liabilities	$10.78M	$9.62M	$8.46M	$13.05M
Total Debt	$3.69M	$3.05M	$2.33M	$1.53M
Total Liabilities	$13.83M	$11.96M	$10.00M	$13.70M
Retained Earnings	-$110.76M	-$177.63M	-$227.21M	-$297.01M
Shareholders' Equity	$327.31M	$277.69M	$242.10M	$212.50M
Working Capital	$324.34M	$274.96M	$239.58M	$210.73M

DSGN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$51.32M	-$58.56M	-$43.10M	-$54.36M
Capital Expenditure	-$918.00K	-$256.00K	-$340.00K	-$193.00K
Free Cash Flow	-$52.23M	-$58.82M	-$43.45M	-$54.55M
Depreciation & Amortisation	$406.00K	$537.00K	$596.00K	$622.00K
Stock-Based Compensation	$10.93M	$13.09M	$13.07M	$14.55M
Investing Cash Flow	-$220.99M	$52.54M	$43.95M	$22.91M
Financing Cash Flow	$235.00K	$724.00K	$513.00K	$25.74M
Net Change in Cash	-$272.07M	-$5.30M	$1.36M	-$5.71M

DSGN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$15.38M	$15.74M	$14.59M	$13.43M	$14.38M
Selling, General & Admin	$5.04M	$5.83M	$4.72M	$4.74M	$5.33M
Operating Expenses	$20.42M	$21.57M	$19.31M	$18.17M	$19.71M
Operating Income	-$20.42M	-$21.57M	-$19.31M	-$18.17M	-$19.71M
EBITDA	-$20.26M	-$21.42M	-$19.16M	-$18.01M	-$19.55M
Pretax Income	-$17.71M	-$19.08M	-$17.00M	-$16.00M	-$17.64M
Net Income	-$17.71M	-$19.08M	-$17.00M	-$16.00M	-$17.64M
Diluted EPS	-0.31	-0.34	-0.30	-0.27	-0.29
Diluted Shares	56.76M	56.86M	56.95M	58.73M	61.43M

DSGN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$13.67M	$19.70M	$15.09M	$16.86M	$12.77M
Receivables	$1.41M	$1.35M	$1.38M	$1.68M	$1.82M
Current Assets	$233.64M	$219.79M	$209.03M	$223.78M	$227.05M
Total Assets	$237.47M	$222.89M	$211.77M	$226.20M	$230.44M
Current Liabilities	$8.24M	$8.75M	$11.17M	$13.05M	$10.19M
Total Debt	$2.14M	$1.95M	$1.74M	$1.53M	$2.73M
Total Liabilities	$9.56M	$9.85M	$12.05M	$13.70M	$12.39M
Retained Earnings	-$244.93M	-$264.01M	-$281.01M	-$297.01M	-$314.64M
Shareholders' Equity	$227.92M	$213.04M	$199.72M	$212.50M	$218.05M
Working Capital	$225.41M	$211.05M	$197.86M	$210.73M	$216.86M

DSGN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$16.79M	-$14.44M	-$11.16M	-$11.97M	-$16.43M
Capital Expenditure	-$72.00K	-$87.00K	—	-$34.00K	—
Free Cash Flow	-$16.86M	-$14.53M	-$11.16M	-$12.00M	-$16.43M
Depreciation & Amortisation	$159.00K	$152.00K	$155.00K	$156.00K	$157.00K
Stock-Based Compensation	$3.54M	$3.98M	$3.59M	$3.44M	$3.92M
Investing Cash Flow	$7.87M	$20.12M	$6.51M	-$11.58M	-$7.59M
Financing Cash Flow	$23.00K	$361.00K	$37.00K	$25.32M	$19.93M
Net Change in Cash	-$8.90M	$6.04M	-$4.62M	$1.77M	-$4.09M

Market Snapshot

About

Design Therapeutics, Inc. is a biotechnology company developing therapies for degenerative diseases caused by nucleotide repeat expansions. The company's GeneTAC (Gene Targeted Chimera) platform aims to eliminate toxic repeat expansion proteins that cause conditions such as Friedreich's ataxia, myotonic dystrophy type-1, and Fuchs endothelial corneal dystrophy. Design Therapeutics' approach uses small molecules designed to target and degrade the aberrant proteins produced by these genetic mutations. The company is advancing multiple programs through clinical development. Design Therapeutics focuses on diseases with significant unmet medical needs where current treatment options are limited.